Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, United States of America.
Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, United States of America.
Int J Cardiol. 2019 Feb 1;276:255-260. doi: 10.1016/j.ijcard.2018.09.028. Epub 2018 Sep 8.
Low diastolic blood pressure (DBP) is associated with increased risk of cardiovascular events. In patients with coronary artery disease (CAD), limitations in coronary blood flow and immune activity are implicated mechanisms, but evidence is lacking. We investigated the association between DBP, biomarkers of myocardial injury, inflammation, immune activation and incident events in patients with CAD.
We studied 2448 adults (mean age 65 ± 12 years, 68% male, median follow-up 4.5 years) with CAD. DBP was categorized into 10 mm Hg increments. Biomarkers of myocardial injury (high sensitivity cardiac troponin-I [hs-cTnI]) and immune activity/inflammation (soluble urokinase plasminogen activator receptor [suPAR]) were dichotomized at their median values. DBP 70-79 mm Hg was used as the referent group, and individuals were followed prospectively for adverse outcomes.
After adjusting for demographic and clinical covariates, individuals with DBP < 60 mm Hg had increased odds of elevated levels of hs-cTnI (OR = 1.68; 95% CI = 1.07, 2.65) and suPAR (OR = 1.71; 95% CI = 1.10, 2.65) compared to the referent group. Additionally, DBP < 60 mm Hg was associated with increased adjusted risk of cardiovascular death or MI (HR = 2.04; 95% CI = 1.32, 3.16) and all-cause mortality (HR = 2.41; 95% CI = 1.69, 3.45).
In patients with CAD, DBP < 60 mm Hg is associated with subclinical myocardial injury, immune/inflammatory dysregulation and incident events. Aggressive BP control may be harmful in these patients, and further investigation is warranted to determine appropriate BP targets in patients with CAD.
舒张压(DBP)较低与心血管事件风险增加有关。在患有冠状动脉疾病(CAD)的患者中,冠状动脉血流受限和免疫活性被认为是潜在机制,但缺乏证据。我们研究了 DBP 与 CAD 患者心肌损伤、炎症、免疫激活和事件发生的生物标志物之间的关系。
我们研究了 2448 名成年人(平均年龄 65±12 岁,68%为男性,中位随访时间为 4.5 年),他们患有 CAD。DBP 分为 10mmHg 递增。心肌损伤的生物标志物(高敏心肌肌钙蛋白 I [hs-cTnI])和免疫活性/炎症的生物标志物(可溶性尿激酶型纤溶酶原激活物受体 [suPAR])以中位数为界分为两类。DBP 70-79mmHg 为参照组,前瞻性随访观察不良结局。
在调整人口统计学和临床协变量后,DBP<60mmHg 的个体发生 hs-cTnI 水平升高(OR=1.68;95%CI=1.07,2.65)和 suPAR 水平升高(OR=1.71;95%CI=1.10,2.65)的几率高于参照组。此外,DBP<60mmHg 与心血管死亡或心肌梗死(HR=2.04;95%CI=1.32,3.16)和全因死亡率(HR=2.41;95%CI=1.69,3.45)的调整风险增加相关。
在 CAD 患者中,DBP<60mmHg 与亚临床心肌损伤、免疫/炎症失调和事件发生有关。在这些患者中,积极的血压控制可能有害,需要进一步研究以确定 CAD 患者的适当血压目标。